Fabhalta

Drug Overview

In the highly specialized field of Immunology, managing disorders where the body attacks its own cells requires precise and innovative treatments. Fabhalta represents a major breakthrough in this area. It is classified as a Complement Factor B Inhibitor and is primarily used to treat a rare, life-threatening blood disease called Paroxysmal Nocturnal Hemoglobinuria (PNH).

Unlike older treatments that required frequent intravenous infusions, Fabhalta offers the convenience of an oral pill. While it is not a traditional Biologic or Monoclonal Antibody, it serves as a highly advanced Targeted Therapy and Immunomodulator. It effectively controls the specific part of the immune system responsible for destroying healthy red blood cells, thereby drastically improving the patient’s quality of life and preventing severe complications like blood clots and organ damage.

• Generic Name: Iptacopan
• US Brand Names: Fabhalta
• Route of Administration: Oral (Capsules)
• FDA Approval Status: FDA-approved for the treatment of adults with Paroxysmal Nocturnal Hemoglobinuria (PNH), as well as specific primary kidney diseases like IgA Nephropathy (IgAN).

What Is It and How Does It Work? (Mechanism of Action)

To understand how Fabhalta works, it is important to understand the “complement system.” This system is a group of proteins in the blood that acts as the immune system’s first line of defense against infections. In patients with PNH, red blood cells are missing a protective shield. Because of this missing shield, the complement system mistakenly identifies these healthy red blood cells as threats and destroys them—a process called hemolysis.

Fabhalta works at the molecular and cellular level by interfering with the “alternative pathway” of the complement cascade.

1. Selective Enzyme Inhibition: Fabhalta directly binds to and blocks a specific immune protein called Factor B.
2. Stopping the Cascade: Factor B is essential for creating an enzyme complex (C3 convertase) that ramps up the immune attack. By blocking Factor B, Fabhalta stops the immune system from tagging red blood cells for destruction.
3. Comprehensive Protection: Older drugs only blocked the complement system at the very end of the process (at a protein called C5), which stopped cells from bursting inside the blood vessels (intravascular hemolysis) but still allowed the liver and spleen to destroy them (extravascular hemolysis). By blocking the process much earlier at Factor B, Fabhalta acts as a Targeted Therapy that prevents both types of red blood cell destruction.

FDA-Approved Clinical Indications

Primary Indication

The primary indication for Fabhalta is the treatment of adults with Paroxysmal Nocturnal Hemoglobinuria (PNH). It is used to stop the destruction of red blood cells, alleviate severe fatigue, and reduce or eliminate the need for frequent blood transfusions.

Other Approved & Off-Label Uses

Because of its ability to quiet the alternative complement pathway, this Immunomodulator is also used and studied for other immune-mediated conditions:

• IgA Nephropathy (IgAN) (Approved to reduce protein in the urine).
• C3 Glomerulopathy (C3G) (Under clinical review).
• Atypical Hemolytic Uremic Syndrome (aHUS) (Off-label/Active research).

Primary Immunology Indications

• Prevention of Cellular Destruction: Prevents the immune system from attacking and destroying vulnerable red blood cells.
• Reduction of Systemic Inflammation: By stopping red blood cells from bursting, it prevents the release of toxic free hemoglobin into the blood, which modulates the overall immune response and prevents systemic inflammation.
• Organ Preservation: Protects the kidneys from damage caused by immune complexes and chronic hemoglobin clearance.

Dosage and Administration Protocols

Fabhalta is taken by mouth, making it a convenient option for patients transitioning from older IV therapies.

Important Adjustments:

• Underlying Infections: Patients must receive vaccinations against encapsulated bacteria (like meningitis and pneumonia) at least two weeks before starting therapy.
• Hepatic Impairment: Fabhalta is not recommended for patients with severe liver impairment.
• Missed Doses: If a dose is missed, it should be taken as soon as possible. However, if it is almost time for the next dose, patients should skip the missed dose. Missing doses can cause sudden, massive red blood cell destruction.

Clinical Efficacy and Research Results

Recent clinical study data (spanning 2020-2026), including the pivotal APPLY-PNH and APPOINT-PNH trials, show that Fabhalta provides remarkable clinical benefits.

In the APPLY-PNH trial, patients who still required blood transfusions while on older C5 inhibitors were switched to Fabhalta. Research data revealed that over 82% of patients taking Fabhalta achieved a sustained hemoglobin increase of 2 g/dL or more without needing any blood transfusions, compared to only 2% of patients who stayed on their old medication. Furthermore, patients reported a dramatic reduction in physical fatigue and a near normalization of their lactate dehydrogenase (LDH) levels, which is the primary inflammatory marker used to measure blood cell destruction.

Safety Profile and Side Effects

BLACK BOX WARNING: SERIOUS INFECTIONS CAUSED BY ENCAPSULATED BACTERIA

Fabhalta carries a strict Boxed Warning. Because it suppresses a vital part of the immune system, patients are at a life-threatening risk for serious infections caused by encapsulated bacteria, such as Neisseria meningitidis, Streptococcus pneumoniae, and Haemophilus influenzae type B. These infections can rapidly become fatal if not treated. Patients must be vaccinated prior to treatment and are monitored under a strict Risk Evaluation and Mitigation Strategy (REMS) program.

Common side effects (>10%)

• Headache.
• Nasopharyngitis (common cold symptoms).
• Diarrhea and abdominal pain.
• Viral upper respiratory tract infections.

Serious adverse events

• Opportunistic Infections: Bacterial meningitis, severe pneumonia, or sepsis.
• Severe Hemolysis After Discontinuation: Stopping the drug suddenly can trigger a massive rebound attack by the immune system, leading to dangerous blood clots or kidney failure.
• Hyperlipidemia: Increases in cholesterol and triglyceride levels.

Management Strategies

To manage infection risks, screening protocols require confirmed vaccination records before the first dose is prescribed. Patients are given a Patient Safety Card to carry at all times, instructing emergency doctors to treat any sudden fever as a potential medical emergency.

Research Areas

Direct Clinical Connections: Ongoing research emphasizes how early intervention with this Targeted Therapy stops the downstream “cytokine storms” that are often triggered by chronic hemolysis. By preventing the constant spillage of cellular debris into the bloodstream, Fabhalta actively prevents the immune system from remaining in a chronic state of high alert.

Generalization: Between 2020 and 2026, the shift from intravenous therapies to oral therapies has been revolutionary. Fabhalta represents a massive advancement in Novel Delivery Systems, providing an oral small-molecule alternative to the heavy Monoclonal Antibody infusions that PNH patients previously relied on for decades.

Severe Disease & Multi-Organ Involvement: In the realm of “Precision Immunology,” clinical trials are heavily focused on how Factor B inhibition prevents severe organ failure. Research shows that Fabhalta significantly slows the decline of kidney function in patients with IgA Nephropathy by stopping immune proteins from getting trapped in the kidney filters, highlighting its powerful role in preventing systemic, multi-organ damage.

Patient Management and Clinical Protocols

Pre-treatment Assessment

• Baseline Diagnostics: A baseline measurement of hemoglobin, Lactate Dehydrogenase (LDH), and reticulocyte count is required to monitor disease activity.
• Organ Function: Liver Function Tests (LFTs) and kidney function panels (like serum creatinine and eGFR) must be documented.
• Screening: A strict review of vaccination history is mandatory. Patients must receive meningococcal vaccines (both MenACWY and MenB) and pneumococcal vaccines at least 14 days before the first dose.

Monitoring and Precautions

• Vigilance: Patients must be closely monitored for signs of infection, such as sudden fever, stiff neck, severe headache, or confusion. Doctors must also monitor for a “loss of response” or breakthrough hemolysis if the patient misses a dose.
• Lifestyle: Patients should follow a nutrient-rich diet to support healthy red blood cell production. Stress management and adequate rest are encouraged to help the body recover from chronic anemia.
• “Do’s and Don’ts” list:
  • DO carry your Patient Safety Card with you at all times.
  • DO go to the emergency room immediately if you develop a fever higher than 100.4 F (38 C), a stiff neck, or an unexplained rash.
  • DO take your medication exactly 12 hours apart to keep the drug levels steady in your body.
  • DON’T stop taking Fabhalta without your doctor’s exact instructions, as this can cause a life-threatening breakdown of your red blood cells.
  • DON’T skip or delay any recommended booster vaccines.

Legal Disclaimer

The medical information provided in this guide is intended for educational and informational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the direct guidance of a qualified healthcare provider or specialist regarding your specific medical condition, prescription medications, and treatment protocols. Do not disregard professional medical advice or delay seeking it because of information read on this website.